Copyright
©The Author(s) 2019.
World J Stem Cells. Sep 26, 2019; 11(9): 650-665
Published online Sep 26, 2019. doi: 10.4252/wjsc.v11.i9.650
Published online Sep 26, 2019. doi: 10.4252/wjsc.v11.i9.650
Table 1 Expandable hepatic cells induced from primary hepatocytes to date
| Hepatocyte source(s) | Chemicals | Growth factor(s) | Medium and supplements | Expansion potential | Yr | |
| Passage count | Doubling time | |||||
| Mouse and Rat | A83-01, CHIR99021, Y-27632 | EGF | DMEM/F12, HEPES, L-proline, ITS, dexamethasone, nicotinamide, ascorbic acid-2 phosphate, BSA, antibiotic/ antimycotic | Rat: >10; Mouse: >20 | Rat: 14.7 ± 1.1 h | 2017[62] |
| Mouse | A83-01, CHIR99021, Y-27632 | EGF, HGF | DMEM/F12, N2 or ITS, S1P, LPA | >30 | 15-20 h | 2017[63] |
| Human (resected patient liver tissue, non-lesion) | A83-01, CHIR99021 | EGF, HGF | DMEM/F-12 (high glucose), FBS, nicotinamide, dexamethasone, ITS, penicillin/ streptomycin | >10 | 37.9-39.8 h | 2018[64] |
| Human (resected patient liver tissue, non-lesion) | A83-01, CHIR99021, Y-27632 | EGF, HGF | Advanced DMEM/F-12, N2, B27, sodium pyruvate, ascorbic acid, S1P, LPA | >10 | 24.7 ± 1.4 h | 2018[67] |
| Human (normal, cryopreserved) | A83-01, Y-27632 | EGF, FGF10, HGF, Wnt3a | Advanced DMEM/F-12, FBS, N2, B27 (minus vitamin A), N-acetylcysteine, nicotinamide, [Leu15]-gastrin I, penicillin/ streptomycin, | 4 (normoxia); 8 (hypoxia) | 2018[68] | |
| Human (normal, freshly isolated and cryopreserved) | A83-01, CHIR99021, Y-27632 | EGF, FGF7, FGF10, HGF, TGFa | Advanced DMEM/F-12, HEPES, B27 (minus vitamin A), R-spodin1 conditioned medium, N-acetylcysteine, nicotinamide, gastrin, GlutaMAX, penicillin/ streptomycin, | Fetal hepatocytes: >16 | 5-7 d | 2018[70] |
Table 2 The specificity and commonality of chemicals in direct lineage conversion
| Compounds | Function | Target germ layer and cell types | Ref. | ||
| Ectoderm: Neural stem/ progenitor cell, neuron | Mesoderm: Cardiomyocyte | Endoderm/ extraembryonic endoderm: Endoderm progenitor cell, XENs | |||
| A83-01 | TGF-βRI (ALK4/5/7) inhibitor | + | + | [42,43,51,53] | |
| AM580 | RAR agonist | + | [25,54] | ||
| AS8351 | KDM5B inhibitor | + | [53] | ||
| Bay K 8644 | Ca2+ channel activator | + | [51] | ||
| BIX01294 | Histone methyltransferase inhibitor | + | + | [42,53] | |
| CHIR99021 | GSK3 inhibitor | + | + | + | [25,41-46,50,51,53-55,78] |
| DMH1 | BMP inhibitor | + | [46] | ||
| EPZ004777 | DOT1L inhibitor | + | [25,54] | ||
| Forskolin | cAMP activator | + | + | + | [25,44-46,50,51,54,55,78] |
| GO6983 | PKC inhibitor | + | [44] | ||
| Hh-Ag1.5 | Smo agonist | + | [43] | ||
| I-BET151 | BET bromodomain inhibitor | + | [78] | ||
| ISX9 | Neurogenic agent | + | [78] | ||
| JNJ10198409 | PDGF-RTK inhibitor | + | [53] | ||
| LDN193189 | BMP type I receptor (ALK2/3) inhibitor | + | [43,45] | ||
| OAC2 | Oct4 activator | + | [53] | ||
| Parnate (Tranylcypromine) | LSD1/MAO inhibitor | + | + | + | [25,43,50,54] |
| PD0325901 | MEK inhibitor | + | [42,45] | ||
| RepSox (616452) | TGF-βRI (ALK5) inhibitor | + | + | + | [25,41,44,46,50,54,55] |
| RG108 | DNA methyltransferase inhibitor | + | [42,43] | ||
| SB431542 | TGF-βRI (ALK4/7) inhibitor | + | [45,78] | ||
| SC1 | ERK1/RasGAP inhibitor | + | [51,53] | ||
| SMER28 | Autophagy modulator | + | [43] | ||
| SP600125 | JNK inhibitor | + | [44,46] | ||
| SU16F | PDGFRβ inhibitor | + | [53] | ||
| TTNPB | RAR agonist | + | + | [50,55] | |
| VPA | Histone deacetylase inhibitor | + | + | + | [25,41,42,44,46,50,54] |
| Y‑27632 | ROCK inhibitor | + | + | + | [44,46,53-55] |
Table 3 Advantages and disadvantages of different strategies for functional cell induction
| Strategy | Induction efficiency | Reproducibi-lity/stability | Target specificity | Cellular function | In vivo engraftment | Safety | Scaling up | Cost | Ref. |
| TF-mediated pluripotent reprogramming followed by differentia-tion | Moderate | Highly reproducible/ stable | High | Immature | Low | Genomic integration; tumorigenesis risk | Expandable before differentia-tion | Very high | [11,97-99] |
| TF-mediated direct lineage conversion | Fast and efficient | Reproducible/stable | High | Deficient | Low | Genomic integration | Expandable in progenitors | High | [100-103] |
| Chemical-mediated pluripotent reprogramming followed by differentia-tion | Controversial | Poorly reproducible/ unstable | Low | Not clear | Not clear | Integration-free | Not clear | Low | [24,25,29,31] |
| Chemical-mediated direct lineage conversion | Low | Reproducible/ unstable | Low | Deficient | Low | Integration-free | Expandable in progenitors | Very low | [18,77,104,105] |
| Chemical-mediated direct lineage expansion | Fast and efficient | Reproducible/ unstable | Low | Close to primary | High | Integration free | Expandable in rodents/ Limited in humans | Very low | [62,64,67,68] |
- Citation: Ge JY, Zheng YW, Liu LP, Isoda H, Oda T. Impelling force and current challenges by chemicals in somatic cell reprogramming and expansion beyond hepatocytes. World J Stem Cells 2019; 11(9): 650-665
- URL: https://www.wjgnet.com/1948-0210/full/v11/i9/650.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i9.650
